Abstract: The present application presents novel peptidomimetic substituted hydroxyethylene compounds, which are inhibitors of beta amyloid cleavage enzyme, capable to permeate the brain and to achieve therapeutic concentrations in the target organ, the brain. These compounds are incorporated in pharmaceutical compositions and applied in the treatment or prophylaxis of neurological disorders or conditions and also other disorders or conditions including Down's syndrome and diabetes.
Type:
Grant
Filed:
April 15, 2016
Date of Patent:
March 20, 2018
Assignee:
IBET—INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA
Inventors:
Helder Joao Ferreira Vila Real, Ana Luisa Ferreira Simplicio, Olga Iranzo Casanova, Christopher David Maycock